Targeting cytokines for treatment of neuropathic pain
- PMID: 29229214
- PMCID: PMC5774983
- DOI: 10.1016/j.sjpain.2017.08.002
Targeting cytokines for treatment of neuropathic pain
Abstract
Background: Neuropathic pain is a challenging condition often refractory to existing therapies. An increasing number of studies have indicated that the immune system plays a crucial role in the mediation of neuropathic pain. Exploration of the various functions of individual cytokines in neuropathic pain will provide greater insight into the mechanisms of neuropathic pain and suggest potential opportunities to expand the repertoire of treatment options.
Methods: A literature review was performed to assess the role of pro-inflammatory and anti-inflammatory cytokines in the development of neuropathic pain. Both direct and indirect therapeutic approaches that target various cytokines for pain were reviewed. The current understanding based on preclinical and clinical studies is summarized.
Results and conclusions: In both human and animal studies, neuropathic pain has been associated with a pro-inflammatory state. Analgesic therapies involving direct manipulation of various cytokines and indirect methods to alter the balance of the immune system have been explored, although there have been few large-scale clinical trials evaluating the efficacy of immune modulators in the treatment of neuropathic pain. TNF-α is perhaps the widely studied pro-inflammatory cytokine in the context of neuropathic pain, but other pro-inflammatory (IL-1β, IL-6, and IL-17) and anti-inflammatory (IL-4, IL-10, TGF-β) signaling molecules are garnering increased interest. With better appreciation and understanding of the interaction between the immune system and neuropathic pain, novel therapies may be developed to target this condition.
Keywords: Anti-inflammatory; Cytokines; Immune modulation; Neuropathic pain; Pro-inflammatory.
Copyright © 2017 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Similar articles
-
Importance of glial activation in neuropathic pain.Eur J Pharmacol. 2013 Sep 15;716(1-3):106-19. doi: 10.1016/j.ejphar.2013.01.072. Epub 2013 Mar 13. Eur J Pharmacol. 2013. PMID: 23500198 Review.
-
Resveratrol attenuates neuropathic pain through balancing pro-inflammatory and anti-inflammatory cytokines release in mice.Int Immunopharmacol. 2016 May;34:165-172. doi: 10.1016/j.intimp.2016.02.033. Epub 2016 Mar 5. Int Immunopharmacol. 2016. PMID: 26953646
-
Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.J Neuroimmune Pharmacol. 2013 Mar;8(1):202-11. doi: 10.1007/s11481-012-9428-2. Epub 2012 Dec 16. J Neuroimmune Pharmacol. 2013. PMID: 23242694 Review.
-
Effect of Ceftiofur on Hyperalgesia and Allodynia in a Rat Neuropathic Pain Model: The Role of Immune Processes.Neuroimmunomodulation. 2017;24(1):21-28. doi: 10.1159/000475757. Epub 2017 Jun 15. Neuroimmunomodulation. 2017. PMID: 28614825
-
Anti-allodynic effect of Buja in a rat model of oxaliplatin-induced peripheral neuropathy via spinal astrocytes and pro-inflammatory cytokines suppression.BMC Complement Altern Med. 2017 Jan 14;17(1):48. doi: 10.1186/s12906-017-1556-z. BMC Complement Altern Med. 2017. PMID: 28088201 Free PMC article.
Cited by
-
Spinal GABAergic disinhibition allows microglial activation mediating the development of nociplastic pain in male mice.Brain Behav Immun. 2023 Jan;107:215-224. doi: 10.1016/j.bbi.2022.10.013. Epub 2022 Oct 21. Brain Behav Immun. 2023. PMID: 36273650 Free PMC article.
-
Analgesic Effect of Noninvasive Brain Stimulation for Neuropathic Pain Patients: A Systematic Review.Pain Ther. 2021 Jun;10(1):315-332. doi: 10.1007/s40122-021-00252-1. Epub 2021 Mar 22. Pain Ther. 2021. PMID: 33751453 Free PMC article. Review.
-
The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives.Pharmaceutics. 2024 Aug 15;16(8):1068. doi: 10.3390/pharmaceutics16081068. Pharmaceutics. 2024. PMID: 39204413 Free PMC article. Review.
-
Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model-In Vivo and In Vitro Study.Int J Mol Sci. 2021 Oct 14;22(20):11074. doi: 10.3390/ijms222011074. Int J Mol Sci. 2021. PMID: 34681732 Free PMC article.
-
Molecular Mechanism of Gelsemium elegans (Gardner and Champ.) Benth. Against Neuropathic Pain Based on Network Pharmacology and Experimental Evidence.Front Pharmacol. 2022 Jan 3;12:792932. doi: 10.3389/fphar.2021.792932. eCollection 2021. Front Pharmacol. 2022. PMID: 35046814 Free PMC article.
References
-
- Callin S, Bennett MI. Assessment of neuropathic pain. Contin Educ Anaesth Crit Care Pain. 2008;8:210–3.
-
- Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PAD, Sturkenboom MCJM. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681–8. - PubMed
-
- Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959–64. - PubMed
-
- Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001;429:23–37. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources